Online Programs

Sort by Expiration Date :

Treating COVID-19 Based on Disease Severity: Key Considerations in Hospitalized Patients

RELEASE DATE: June 07, 2022

EXPIRATION DATE: June 07, 2023

This activity is designed to meet the educational needs of, and provide tools for the entire healthcare community. Participants will range from a variety of specialties, including infectious disease specialists, pulmonary medicine specialists, emergency room practitioners, primary care, advanced practitioners, nurses, paramedics, and other healthcare professionals to help support them in their effort to optimize care of patients with COVID-19.

Learn More & View Event »

Updates in COVID-19 Therapies: What You Need to Know to Optimize Care of Hospitalized Patients in 2022

This activity is designed to meet the educational needs of intensive care physicians, pulmonologists, rheumatologists, infectious disease specialists, emergency physicians, hospitalists, pharmacists, nurses, nurse practitioners, physician assistants, and other members of the multidisciplinary team to ensure optimal patient outcomes in the inpatient management of COVID-19 infection.

Learn More & View Event »

Identifying Patients at High Risk of COVID-19 Complications: Considerations for Community Care to Reduce Morbidity, Mortality, and Hospitalization Risk

This activity is designed to meet the educational needs of primary care physicians, internists, pharmacists, nurses, nurse practitioners, physician assistants, and other members of the multidisciplinary team to ensure optimal patient outcomes in outpatient management of COVID-19 infection and potential complications of disease in at-risk populations.

Learn More & View Event »

Updating Outpatient Recommendations in COVID-19 Management: Identifying Opportunities for Risk Reduction in Non-Hospitalized Patients

This program will be designed to meet the educational needs of primary care physicians, internists, pharmacists, nurses, nurse practitioners, physician assistants, and other members of the multidisciplinary team to ensure optimal patient outcomes in outpatient management of COVID-19 infection and potential complications of disease in at-risk populations.

RELEASED DATE: May 12, 2023
EXPIRATION DATE: May 12, 2024

Learn More & View Event »

Updating Outpatient Recommendations in COVID-19 Management: Identifying Opportunities for Risk Reduction in Non-Hospitalized Patient

RELEASED DATE: May 18, 2023
EXPIRATION DATE: May 18, 2024

This program is designed to meet the educational needs of primary care physicians, internists, pharmacists, nurses, nurse practitioners, physician’s assistants, and other members of the multidisciplinary team to ensure optimal patient outcomes in outpatient management of COVID-19 infection and potential complications of disease in at-risk populations.

Learn More & View Event »

Identifying Appropriate High-Risk Patients and Managing Drug-Drug Interactions with Outpatient Antiviral Therapy: Assessing Current Best Practices in 2023

RELEASED DATE: May 19, 2023
EXPIRATION DATE: May 19, 2024

This activity is designed to meet the educational needs of primary care physicians, internists, pharmacists, nurses, nurse practitioners, physician’s assistants, and other members of the multidisciplinary team to ensure optimal drug-drug interaction management in outpatient management of COVID-19 infection.

Learn More & View Event »
Scroll to Top
Menu

Updates in the Treatment and Prevention of COVID-19​

Bebtelovimab Is the Only Monoclonal Antibody That Retains Activity Against Omicron Subvariants

The Omicron subvariants BA.2 and BA.2.12.1 now account for 99% of all COVID-19 cases in the United States. Studies assessing the neutralizing activity of monoclonal antibodies for the treatment of COVID-19 have found that only bebtelovimab retains activity against BA.2 and BA.2.12.1. Other monoclonal antibodies, including sotrovimab, bamlanivimab, etesevimab, casirivimab, and imdevimab, are not effective against these new subvariants and are not currently authorized by the US Food and Drug Administration (FDA) to treat COVID-19 due to the high incidence of Omicron BA.2.

Bebtelovimab is authorized for emergency use by the FDA for the treatment of mild-to-moderate COVID-19 in patients 12 years and older weighing at least 40 kg with positive results of direct SARS-CoV-2 viral testing who are at high risk for progression to severe COVID-19, including hospitalization or death. Bebtelovimab should be administered as soon as possible after positive SARS-CoV-2 results and within 7 days of symptom onset.

FDA Approves Baricitinib for Hospitalized COVID-19 Patients

Baricitinib, an oral Janus kinase (JAK) inhibitor, is now FDA-approved for the treatment of COVID-19 in hospitalized adults requiring supplemental oxygen, noninvasive or invasive mechanical ventilation, or extracorporeal membrane oxygenation (ECMO). It is also authorized for emergency use by the FDA for hospitalized pediatric patients between 2 and 18 years of age who require oxygen support. The approval of baricitinib is based on efficacy and safety data from the ACTT-2 and COV-BARRIER clinical trials. In ACTT-2, baricitinib plus remdesivir was superior to remdesivir alone in reducing recovery time, particularly in patients receiving high-flow oxygen or noninvasive ventilation (10 days vs 18 days; rate ratio for recovery, 1.51; 95% confidence interval (CI), 1.10 to 2.08). The 28-day mortality was 5.1% with baricitinib plus remdesivir and 7.8% with remdesivir alone (hazard ratio [HR] for death, 0.65; 95% CI, 0.39 to 1.09). The COV-BARRIER trial found that baricitinib, in addition to standard of care (SoC), was associated with reduced 28-day mortality in hospitalized adults with COVID-19 compared with SoC alone (8% vs 13%; HR, 0.57; 95% CI, 0.41 to 0.78; P= .0018). The 60-day all-cause mortality was 10% with baricitinib plus SoC versus 15% with SoC (P= .005).

References:
Baricitinib fact sheet for healthcare providers. May 2022. (https://www.fda.gov/media/143823/download).  Accessed 5.24.2022.

Baricitinib (Olumiant®) PI 2022 (https://pi.lilly.com/us/olumiant-uspi.pdf). Accessed 5.24.2022.

Bebtelovimab fact sheet for healthcare providers. May 2022. (https://www.fda.gov/media/156152/download).  Accessed 5.24.2022.

Centers for Disease Control and Prevention (CDC). COVID data tracker. May 23, 2022. (https://covid.cdc.gov/covid-data-tracker/#variant-proportions). Accessed 5.24.2022.

Iketani S, et al. Antibody evasion properties of SARS-CoV-2 Omicron sublineages. Nature. 2022;604:553-556.

Kalil AC, et al. Baricitinib plus remdesivir for hospitalized adults with COVID-19. N Engl J Med. 2021;384:795-807.

Marconi VC, et al. Efficacy and safety of baricitinib for the treatment of hospitalised adults with COVID-19 (COV-BARRIER): a randomised, double-blind, parallel-group, placebo-controlled phase 3 trial. Lancet Resp Med. 2021;9:1407-1418.